Medicamen Biotech Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.8 pts less than Nifty Microcap 250 and 5.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Medicamen Biotech submitted its unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025. On a standalone basis, nine-month profit after tax came in at roughly ₹644 lakh versus about ₹705 lakh in the same period last year, a modest decline of around 9%, with Q3 standalone PAT nearly flat at about ₹259 lakh versus ₹252 lakh. Consolidated nine-month PAT improved to about ₹531 lakh from about ₹469 lakh, helped by subsidiaries. Revenue was broadly flat year-on-year. The statutory auditors, Rai Qimat & Associates, issued an unqualified limited review report with no qualifications. Separately, Independent Directors Mr. Harish Pande and Mr. Arun Kumar ceased on completion of their second five-year term on February 13, 2026, prompting reconstitution of the Audit, Stakeholders Relationship, Nomination & Remuneration, Risk Management, and CSR committees.
Mixed quarterly performance — consolidated numbers improved while standalone earnings softened slightly, suggesting margin pressure at the parent level but a better contribution from subsidiaries. The director exits are routine tenure completions, not a governance red flag, though investors may watch how quickly the committees are reconstituted with new independent directors.